Thursday, July 28, 2016
Tuesday, December 29, 2015
TRUST project starts
“Creating and enhancing TRUSTworthy, responsible and equitable partnerships in international research”
Co-funded by the
European Commission, TRUST main objective is to reduce the risk
of exporting non ethical practices, that-is-to-say ‘ethics dumping’, in all the
fields of research to low and middle income countries (LMICs). As a Coordination and Support
Action of Horizon 2020, this is not a research project. TRUST is thus aimed to catalyse a global collaborative
effort to improve adherence to high ethical standards in research in LMICs. The
implementation of TRUST just starts, and will end at the end of 2018.
Context:
Globalization of research activities
is raising the risk of developing research sensitive ethical issues being conducted by
European organisations outside the EU without proper compliance structures and
follow‐up. This
phenomenon has highlighted gaps in global research ethics governance. Several
governance frameworks and standards to guide research activities have been
initiated, but there are disparate and lacking a guiding vision. That is why TRUST will use
existing frameworks and tools in order to reinforce and enhance them.
Project overview:
‘Ethics dumping’
means both purposeful exploitation of third country research
participants/resources as well as exploitation based on insufficient ethics
awareness. In this respect, the project is built on an interdisciplinary
collaboration between multi-level actors (e.g. ethics bodies, policy makers,
civil society organisations, funding organisations, industry and academic
scholars), an essential aspect to get a global view on the ethics issue, to
receive wide responses, and to target a large public.
During three years,
the TRUST international consortium and its networks will collaborate to create
and start implementing three tools preventing from ethics dumping: a Global
Code of conduct, designed for funders and researchers especially, containing
major principles of equitable research partnerships; on-line Fair Research
Contracts protecting vulnerable populations involved in research and ensuring
fair benefits-sharing; and a Compliance and ethics follow-up designed for a wide use, for all
stakeholders.
Activities are based
on case studies involving local structures in countries where the research
takes place and impacts population. In addition to internal production of case
studies, a bottom-up call for competition with 2,000€ to win has been launched
in order to collect original case studies (deadline March the 2nd,
2016), for instance misuse of health technologies. English and French application
form is available at the following link: http://www.progressproject.eu/news/2208-case-competition-reducing-the-risk-of-exporting-unethical-research-practices/
To reinforce the
guiding vision of TRUST, a funder and industry platform of dialogue is been
designed to co-ordinate and support activities of the TRUST partners. Indeed
funders are powerful agents in achieving high ethical standards globally,
having already a legal requirement to comply with their financial instruments.
The TRUST project is
a stimulus to then allow the international community to take over. Global adherence
to high ethical standards and the sustainability of the impact of TRUST’s
mission will be ensured through the establishment of a global network by the
development of a collaboration platform, creating an international forum for
exchange of information and views, and establishing confidence between
stakeholders.
Thursday, July 30, 2015
Aviesan-Inserm is present in the proposal winner of the H2020 call 'Reducing the risk of exporting non ethical practices to third countries'
This 18-month proposal named 'Creating and enhancing TRUSTworthy, responsible and equitable partnerships in international research' (TRUST), aims at proposing the analysis of research conducted in low and middle income countries which can pose an ethical risk. Drafting recommendations to anticipate or avoid them, is also required by the tender. This project coordinated by the University of Lancachire (UK) brings together 13 partners from Europe (UK, France, Switzerland), Asia (India) and Africa (Kenya, South Africa). The partnership includes academic (including Inserm), NGOs (including Action contre la faim), the European institutions (EDCTP) and an international organization (UNESCO). Finally, the consortium will benefit from the advice of a broad panel of academic experts and also representatives of institutions such as the Wellcome Trust and the Council of Europe.Sunday, November 2, 2014
![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj3Jel-fQ03zLuVlkny-p91YBPo7sS140FJcEafhsiYsNSwM0D7mhutb78k9J4vrckvCvFg4IjP34Khw4VDAGXY65omWFH6xrBW_8CJDVf-s1u8TCrwL5CtCtou62qYnADwZsfmtYPannUd/s1600/VIetnam.jpg)
Monday, July 28, 2014
EDCTP 2 is back with new opportunities!
The European and Developing Countries Clinical Trials Partnership (EDCTP) was created in 2003 as a European response to the global health crisis caused by the three main poverty-related diseases of HIV/AIDS, tuberculosis and malaria. EDCTP aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria, with a focus on phase II and III clinical trials in sub-Saharan Africa.
On 6 May 2014, the Council of the European Union (EU) approved the participation of the EU in the second phase of the EDCTP programme (EDCTP2). With an EU contribution of € 683 million for the 10-year programme period and additional contributions from Participating States and third parties, EDCTP2 will continue to support the clinical development of new or improved diagnostics, drugs, vaccines and microbicides against HIV/AIDS, tuberculosis, and malaria.However, EDCTP2 will now support research on neglected infectious diseases (NIDs).
EDCTP2 will continue to promote and support:
* Multicentre projects that combine clinical trials, capacity building and networking
* Capacity development for clinical trials and clinical research in developing countries
* Fellowships
* Closer collaboration with industry, like-minded organisations, funders of global health research and development cooperation agencies.
The geographical focus of EDCTP2’s activities will remain on sub-Saharan Africa, although collaborative research with other developing countries outside sub-Saharan Africa could be envisioned when possible and desirable.
The first call 'Diagnostic tools for poverty-related diseases' has just been published at http://www.edctp.org/calls-and-grants/calls-for-proposals/diagnostic-tools-for-poverty-related-diseases/
As a result of the possibility to support research on neglected infectious diseases, the project anticipated with DNDi (see blog April 25th, 2013 ) will be revitalized and a meeting with DNDi is planned soon in Geneva.
Also, given the possibility to extend now collaboration with other developing countries out of Africa, the potential evaluation of a low-cost PCR-based TB diag tool designed by CTGen (see blog August, 2013) in Africa, is under consideration.
Friday, January 17, 2014
Meeting La Paillasse
We received
the visit of a member of the French association La Paillaisse which defines
itself as a “biohackerspace” and which
belongs to the international movement DIY BIO (Do-It-Yourself Biologist). The aim is to build biological projects made
available to all in term of direct participation and in term of sharing results
and technologies. The design of materials such as UV- transilluminator, cell centrifuge… are some of the projects in
progress with the ultimate goal to permit every one, everywhere to do the same
(no licencing, publishing of the whole procedures).We
discussed the possibilities to forward this information to our partners, NGOs
and scientists working in LMICs.
You may contact La Paillasse at adrienclavairoly@hotmail.com
You may contact La Paillasse at adrienclavairoly@hotmail.com
Monday, September 16, 2013
Meeting CTGen
We recently
met Dr NGO Nam in Aviesan premises, the owner of CTGen
a company based in California which provides easy-to-use DNA synthesis supports. Dr NGO also developed a sister company in Vietnam CTGEN-PSA which aims at facilitating the use of PCR in LMICs. Dr NGO will make all efforts to attend the AEC Biomedical Innovation Forum 2013, the international conference and exhibition on Health Technology for Development co-organised by Aviesan and the National Innovation Agency of Thailand scheduled 14 - 16 November 2013 in Bangkok
http://www.nia.or.th/biomed2013/
August, 2013
a company based in California which provides easy-to-use DNA synthesis supports. Dr NGO also developed a sister company in Vietnam CTGEN-PSA which aims at facilitating the use of PCR in LMICs. Dr NGO will make all efforts to attend the AEC Biomedical Innovation Forum 2013, the international conference and exhibition on Health Technology for Development co-organised by Aviesan and the National Innovation Agency of Thailand scheduled 14 - 16 November 2013 in Bangkok
http://www.nia.or.th/biomed2013/
August, 2013
Subscribe to:
Posts (Atom)